Inhibiting LOC333588 isoform X1, a protein involved in essential cellular processes, requires the interruption of specific signaling pathways and enzymatic activities. This inhibition is achieved through various chemical inhibitors, each targeting different aspects of cellular signaling and protein function. Staurosporine, LY294002, Wortmannin, Dasatinib, Erlotinib, Imatinib, and Lapatinib are critical in this process due to their ability to target key proteins and pathways that regulate or influence the activity of LOC333588 isoform X1. Staurosporine's broad-spectrum inhibition of protein kinases can prevent phosphorylation, an essential post-translational modification necessary for the activation or functional modification of LOC333588 isoform X1. LY294002 and Wortmannin, as PI3K inhibitors, disrupt signaling pathways critical for LOC333588 isoform X1's functionality, leading to its functional inhibition.
Furthermore, Rapamycin's targeting of the mTOR pathway directly impacts protein synthesis and cellular growth processes, which are vital for LOC333588 isoform X1's function or post-translational modifications. Inhibitors like PD98059, SB203580, SP600125, and U0126, which target the MAPK/ERK, p38 MAPK, and JNK pathways, are involved in various cellular processes, including stress responses and regulation, likely important for LOC333588 isoform X1's functionality. By inhibiting these pathways, these chemicals lead to a decrease in the functional activity of LOC333588 isoform X1. Erlotinib, Imatinib, and Lapatinib, as tyrosine kinase inhibitors, further contribute to the inhibition by targeting EGFR, BCR-ABL, c-Kit, PDGFR, and HER2/neu. The inhibition of these kinases leads to a reduction in the functional activity of LOC333588 isoform X1 by disrupting the signaling cascades crucial for its functional state. The collective action of these inhibitors, through their specific targets, contributes to the functional inhibition of LOC333588 isoform X1, demonstrating the intricate interplay between cellular signaling pathways and protein functionality.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases, potentially blocking phosphorylation essential for LOC333588 isoform X1's activation or modification. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, disrupting signaling pathways crucial for LOC333588 isoform X1's activity, leading to functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, impacting protein synthesis and growth processes vital for LOC333588 isoform X1's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK in the MAPK/ERK pathway, reducing ERK activity and potentially inhibiting LOC333588 isoform X1's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, affecting stress response pathways and reducing LOC333588 isoform X1's functional activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, impacting cellular processes and reducing LOC333588 isoform X1's functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2 in the MAPK/ERK pathway, potentially reducing LOC333588 isoform X1's activity by affecting downstream targets. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, disrupts signaling pathways, leading to functional inhibition of LOC333588 isoform X1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits tyrosine kinases, reducing LOC333588 isoform X1's activity by affecting relevant signaling pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase, essential for LOC333588 isoform X1's function, leading to reduced activity. | ||||||